INS and type 2 diabetes mellitus: On the other hand, Cavelti-Weder et al. showed that the treatment with gevokizumab, a novel human-engineered monoclonal anti-IL-1β antibody, improved glycemia by restoring insulin production/action and reduced inflammation in patients with T2DM [163].